Dr.Jignesh Gala Retina Surgeon

Macular Degeneration Specialist in Andheri West — AMD in 2026: Injections, Monitoring & Honest Hope

/ Retina Services / By

Macular Degeneration Specialist in Andheri West — AMD in 2026: Injections, Monitoring & Honest Hope

Written & medically reviewed by Dr. Jignesh Gala, Vitreoretinal & Cataract Surgeon (FRCS Glasgow), Founder & Director — Crystal Clear Eye Clinic (Andheri West) and Topax Eye Hospital (Vile Parle East), Mumbai. Facts verified: 24 July 2026.

Thank you for reading this post, don't forget to subscribe!

⚡ Quick answer: Age-related macular degeneration (AMD/ARMD) damages the macula — the retina’s central “high-definition zone” — blurring faces, reading and driving while side vision survives. Dry AMD is managed with AREDS2 supplements, diet and monitoring; wet AMD with anti-VEGF injections (₹8,000–38,000 by drug — Eylea’s MRP dropped from ₹53,141 to ₹29,998 in April 2026). AMD cannot be “cured,” but caught early, most patients keep useful vision for life. Looking for a macular degeneration specialist in Andheri West? Dr. Jignesh Gala (FRCS Glasgow) treats AMD at Crystal Clear Eye Clinic and Topax Eye Hospital, Vile Parle East. Call 077188 85245.

🔎 Popular guides by Dr. Gala:

1. What AMD Is (Dry vs Wet)

The macula is a few millimetres of retina responsible for everything you look at — faces, phone screens, currency notes. With age, its support layer wears out. AMD never causes total blindness (side vision survives), but it takes the vision you use most. In India 2026 — longer lives, imaging everywhere — AMD is among the commonest reasons patients over 55 walk into our Andheri West clinic.

Two forms, very different behaviour:

Dry AMD (~85–90% of cases)Wet AMD (~10–15%, most vision loss)
What happensDrusen (yellow deposits) accumulate; macular cells slowly thinAbnormal vessels grow under the macula and leak
SpeedSlow — years to decadesFast — weeks can scar the macula
SymptomsGradual dimming, needing brighter light, washed-out coloursStraight lines look bent; a grey/black central spot
TreatmentAREDS2 supplements, lifestyle, monitoringAnti-VEGF injections — the earlier, the better

Risk factors: age over 60, smoking (the biggest modifiable one), family history, high BP and cholesterol, obesity, unprotected sun exposure, low-green-vegetable diet. A word on drusen: small ones are harmless; large, soft drusen mean your retina needs scheduled monitoring — not panic, not neglect. Any macular degeneration specialist in Andheri West worth the title grades your drusen on OCT and tells you plainly where you stand. Look-alikes exist too — central serous retinopathy, myopic degeneration, even early glaucoma — so self-diagnosis from Google images is a bad plan.

Macular degeneration specialist in Andheri West — retinal evaluation for AMD at Crystal Clear Eye Clinic, Mumbai
AMD evaluation at Crystal Clear Eye Clinic, Andheri West — drusen graded on OCT, not guessed.

2. Wet AMD Treatment in 2026

Wet AMD is the emergency form — and the one with the best treatment story of the last two decades. Anti-VEGF injections (aflibercept/Eylea, ranibizumab, faricimab, biosimilars) block the signal that grows leaky vessels. A 2-minute procedure after numbing drops dries the macula in days — and in a third or more of patients actually improves vision.

What’s genuinely new in 2026:

  • The Eylea April-2026 price cut: aflibercept’s MRP dropped from ₹53,141 to ₹29,998 — a ~44% fall moving a premium molecule within reach of far more Indian families (verified 24 July 2026).
  • Faricimab and longer intervals: the newest molecule blocks two pathways (VEGF-A and Ang-2) and held vision gains at intervals up to every 16 weeks in the phase-3 TENAYA/LUCERNE trials (Lancet 2022), durable at two years (Ophthalmology 2024). Fewer visits, same control — a big win for elderly patients from Goregaon, Malad or Kandivali.
  • Biosimilars arriving: quality biosimilars bring effective treatment into the ₹8,000–15,000 bracket.
  • Treat-and-extend discipline: inject, then stretch the interval while the OCT stays dry — tighten at the first sign of fluid. The goal: the fewest injections that keep your macula dry.

This molecule family keeps proving itself across retinal disease — four-year durability data (RHONE-X, 2026) and strong vein-occlusion results (BALATON/COMINO, 2024) show why a specialist who follows the literature offers options a decade-old practice cannot. Rarely, wet AMD bleeds massively and needs surgical evacuation — see best vitrectomy surgery in Mumbai — expert retinal care.

3. Monitoring: OCT Every Visit + Home Amsler Grid

AMD management lives or dies on monitoring — how inject-vs-observe decisions are actually made at our centres:

  • OCT at every visit: the scan shows retinal fluid down to microns. Dry scan → extend the interval. Fluid → inject. This discipline is why modern AMD patients keep reading vision their parents’ generation lost.
  • Vision + examination: every visit logs reading vision and a dilated macular check — numbers never replace the doctor’s eye.
  • Home Amsler grid: a printed grid checked daily, one eye at a time. Lines suddenly bending or a new grey patch = same-week appointment. Dry AMD converts to wet in 10–15% of patients — the grid catches conversion this week.
  • One eye protects the other: wet AMD in one eye raises the other’s risk, so both are monitored even when only one is injected.
Macular degeneration specialist in Andheri West examining AMD patient — OCT-guided monitoring at Crystal Clear Eye Clinic Mumbai
Every AMD visit ends with a decision made on the OCT scan — inject, extend, or observe.

4. Dry AMD & Prevention

Dry AMD has no injection (yet) — but it is far from “nothing can be done”:

  • AREDS2 supplement formula (vitamin C, E, zinc, copper, lutein, zeaxanthin) cuts progression risk ~25% in intermediate AMD — for that stage specifically, not a general eye tonic; smokers must avoid beta-carotene versions.
  • Quit smoking. Full stop — the strongest modifiable risk factor, and it blunts treatment response too.
  • Eat for your retina: dark leafy greens (palak, methi), colourful vegetables, fish twice a week, nuts. Screen hours do not cause AMD, but they cause real strain — see understanding and preventing digital eye strain.
  • UV protection: good sunglasses outdoors; control BP, cholesterol, weight.
  • Cataract can coexist: lens choice in AMD needs retinal judgment — read our Premium IOL Selection Guide 2026 and Laser Cataract Surgery in Andheri pages first.

When dry converts to wet: new distortion, a sudden central smudge, or rapid dimming over days = same-week OCT. Early-caught conversions respond dramatically better. More on our Eye Health Blog.

5. AMD Treatment Costs in Mumbai (2026)

Honest, date-stamped guidance (verified 24 July 2026). AMD is a long game — per-injection price and frequency together decide your annual cost; a cheap drug needing monthly visits can cost more yearly than a durable one:

ItemTypical Mumbai Range (2026)Notes
Specialist consultation₹800–1,500Includes dilated macular examination
OCT scan₹1,500–3,000 per eyeAt every monitoring visit
OCT angiography (OCTA)₹3,500–5,000Dye-free vessel mapping
Anti-VEGF — biosimilar segment~₹8,000–15,000 per injectionBest budget option
Anti-VEGF — originator ranibizumab~₹15,000–25,000 per injectionLong track record
Eylea (aflibercept)MRP ₹29,998 (was ₹53,141 before April-2026 cut)Premium molecule, ~44% cheaper
Newest-generation (e.g., faricimab)up to ~₹38,000 per injectionLonger intervals can cut annual cost

Overall, anti-VEGF in Mumbai spans ₹8,000–38,000 per injection by drug. Exact pricing for your drug and eye — call 077188 85245; we quote numbers, not runarounds.

6. Why Patients Choose Dr. Jignesh Gala as Their Macular Degeneration Specialist in Andheri West

Dr Jignesh Gala — macular degeneration specialist in Andheri West, Mumbai for AMD injections and monitoring
Dr. Jignesh Gala, FRCS (Glasgow) — AMD care built on OCT-guided treat-and-extend protocols

Dr. Jignesh Gala — FRCS (Glasgow), MRCS (Edinburgh), FICO, vitreoretinal fellowship from L.V. Prasad Eye Institute — owns and directs both Crystal Clear Eye Clinic (Andheri West) and Topax Eye Hospital (Vile Parle East). AMD is a decades-long condition; it deserves one doctor who knows your scans year after year.

✅ Injection decisions by the surgeon himself: every OCT read by Dr. Gala, every inject/extend call explained on the screen — never delegated.

✅ Fully aware of the latest research — unlike old practitioners who stopped reading journals years ago: treat-and-extend protocols, Eylea price-cut economics, faricimab durability — your plan reflects 2026, not 2010. Six years as a BMJ Case Reports peer reviewer keeps it that way.

✅ Trained at the top, practised across borders: founding ophthalmology team of Woodlands Health Singapore; ex-Assistant Professor, B.Y.L. Nair Hospital. More on About Crystal Clear Eye Clinic.

✅ The full retina ladder under one roof: if AMD ever needs more than injections, your specialist is already a vitreoretinal surgeon — among the best retina specialists in Mumbai.

✅ Honest drug counselling: the molecule your eye and budget need — biosimilar, Eylea or faricimab — with the reason told to you.

7. Locations — Macular Degeneration Specialist in Andheri West & Vile Parle East

1) Crystal Clear Eye Clinic — Andheri West

📍 Address: Laram Centre CHS, A1-202, Swami Vivekanand Road, above Sunil Jewellers, near NADCO Shopping Centre, Railway Colony, Andheri West, Mumbai 400058 • Open daily, closes 9 pm.
📞 Phone: 077188 85245 • 💬 WhatsApp Us • Contact & Directions — Andheri West
💳 Third-party/TPA cashless is done through Crystal Clear Eye Clinic (Andheri West).

Minutes from Andheri station, Lokhandwala, Versova, Yari Road, Juhu, Oshiwara, DN Nagar, Seven Bungalows, Azad Nagar, Veera Desai Road, Jogeshwari and Amboli; Bandra, Khar, Santacruz, Goregaon, Malad and Kandivali reach us in 20–30 minutes. The clinic covers the family’s other eye needs too, from LASIK surgery in Andheri for the children to senior eye care for the parents.

AMD care team at Topax Eye Hospital Vile Parle East — macular degeneration treatment near Andheri Mumbai
The Topax Eye Hospital team, Vile Parle East — injections and full retinal surgery backup.

2) Topax Eye Hospital — Vile Parle East

📍 Vile Parle East, Mumbai (call for the exact address & directions) • 📞 077188 85245 • Open daily, closes 9 pm.
💳 Direct cashless is done through Topax Eye Care (Vile Parle East).

Convenient for Santacruz East, Khar, Bandra East, Kalina, Vakola, Juhu and the airport corridor. As a full hospital, Topax handles everything AMD can demand — OCT, injections, surgery — under Dr. Gala himself.

8. हिंदी • मराठी • ગુજરાતી — Patient Summaries

🇮🇳 हिंदी सारांश — मैक्युलर डीजेनरेशन (AMD)

उम्र के साथ रेटिना का बीच का हिस्सा (मैक्युला) कमज़ोर होता है — चेहरे और पढ़ना धुंधला, साइड की नज़र बची रहती है। सूखा (dry) AMD में AREDS2 सप्लीमेंट और निगरानी; गीला (wet) AMD में anti-VEGF इंजेक्शन असरदार — Eylea की MRP अब ₹29,998 (April 2026 कट के बाद)। अंधेरी वेस्ट में मैक्युलर डीजेनरेशन स्पेशलिस्ट डॉ. जिग्नेश गाला — क्रिस्टल क्लियर आई क्लिनिक और टोपैक्स आई हॉस्पिटल, विले पार्ले ईस्ट। अपॉइंटमेंट: 077188 85245।

🚩 मराठी सारांश — मॅक्युलर डीजेनरेशन (AMD)

वयानुसार मॅक्युलाची (मधली नीट दिसणारी पट्टी) क्षमता कमी होते — चेहरे व वाचन अंधूक, बाजूची दृष्टी वाचते. कोरड्या (dry) AMD मध्ये AREDS2 सप्लिमेंट व नियमित तपासणी; ओल्या (wet) AMD मध्ये anti-VEGF इंजेक्शन परिणामकारक — Eylea ची MRP आता ₹२९,९९८ (एप्रिल २०२६ कपातीनंतर). अंधेरी वेस्टमध्ये मॅक्युलर डीजेनरेशन तज्ज्ञ डॉ. जिग्नेश गाला — क्रिस्टल क्लियर आय क्लिनिक व टोपॅक्स आय हॉस्पिटल, विले पार्ले ईस्ट. भेटीसाठी: 077188 85245.

🟡 ગુજરાતી સારાંશ — મેક્યુલર ડીજેનરેશન (AMD)

ઉંમર સાથે મેક્યુલા (વચ્ચેનો સ્પષ્ટ દ્રષ્ટિ ભાગ) નબળો પડે છે — ચહેરા અને વાંચન ઝાંખા, બાજુની નજર બચી રહે. સૂકા (dry) AMD માં AREDS2 સપ્લિમેન્ટ અને દેખરેખ; ભીના (wet) AMD માં anti-VEGF ઇન્જેક્શન અસરકારક — Eylea ની MRP હવે ₹૨૯,૯૯૮ (એપ્રિલ ૨૦૨૬ ઘટાડા પછી). અંધેરી વેસ્ટમાં મેક્યુલર ડીજેનરેશન સ્પેશિયાલિસ્ટ ડૉ. જિગ્નેશ ગાલા — ક્રિસ્ટલ ક્લિયર આય ક્લિનિક અને ટોપેક્સ આય હોસ્પિટલ, વિલે પાર્લે ઇસ્ટ. એપોઈન્ટમેન્ટ: 077188 85245.

Dr Jignesh Gala in scrubs — macular degeneration specialist in Andheri West performing anti-VEGF injection Mumbai
Every anti-VEGF injection is performed by Dr. Gala himself — 2 minutes that protect reading vision.

9. ❓ 8 Frequently Asked Questions (English + Hinglish)

1. Macular degeneration kya hota hai?

Aankh ke retina ka beech ka hissa — macula — umar ke saath kharab hone lagta hai. Beech ki nazar (chehre pehchanna, padhna) dhundhli hoti hai; side ki nazar bani rehti hai. Do type: dry (dheere chalta hai) aur wet (nayi leaky nasein, jaldi nuksan). Dono mein shuru mein koi dard nahi — isliye 55+ ke baad regular retina check zaroori hai.

2. Is AMD curable? Kya AMD ka ilaaj hai?

Honest jawab: AMD poori tarah “cure” nahi hota — lekin control zaroor hota hai. Wet AMD mein injections se fluid sukhta hai aur kai patients ki vision improve hoti hai. Dry AMD mein AREDS2 progression ~25% slow karte hain. Jaldi pakde gaye AMD mein zyada tar log zindagi bhar kaam ki nazar banaye rakhte hain — der hi asli dushman hai.

3. Wet AMD injection cost in Mumbai kitna hai?

Drug ke hisaab se ₹8,000–38,000 per injection (verified 24 July 2026). Biosimilars ~₹8,000–15,000; Eylea ka MRP April-2026 cut ke baad ₹53,141 se ₹29,998. Consultation (₹800–1,500) aur OCT (₹1,500–3,000/eye) alag se. Exact price ke liye call 077188 85245.

4. How many injections will I need for wet AMD?

Usually 3 monthly loading injections, then treat-and-extend: the interval stretches to 8, 12, even 16 weeks while the OCT stays dry, and tightens if fluid returns. Some patients settle at 3–4 injections a year; aggressive disease needs more. Your exact number is written by your OCT, not a fixed formula.

5. AMD mein vision wapas aata hai kya?

Wet AMD mein — haan, kaafi baar. Injection se macula sookhta hai aur lagbhag one-third patients ki vision improve hoti hai; baaki stable rehti hai. Lekin jo scarring ho chuki hai wo wapas nahi aati — isliye jaldi treatment crucial hai. Dry AMD mein supplements se speed slow hoti hai. Amsler grid se roz check karein — nayi distortion dikhe toh usi hafte dikhaein.

6. Which foods/supplements help in macular degeneration?

AREDS2 formula (vitamin C, E, zinc, copper, lutein, zeaxanthin) is the only supplement with strong trial evidence — for intermediate/advanced dry AMD specifically; smokers avoid beta-carotene versions. Food: dark leafy greens (palak, methi), colourful sabziyan, fish, nuts. Smoking quit karna sabse bada “supplement” hai — random multivitamins se AMD nahi rukta.

7. Macular degeneration specialist kahan hain Andheri West mein?

Dr. Jignesh Gala (FRCS Glasgow; retina fellowship, L.V. Prasad) — Crystal Clear Eye Clinic, Laram Centre CHS, A1-202, S.V. Road, above Sunil Jewellers, near NADCO Shopping Centre, Andheri West 400058; ya Topax Eye Hospital, Vile Parle East. Phone: 077188 85245. Open daily, closes 9 pm. Also listed among the best eye specialists in Andheri.

8. What is the Amsler grid test?

A simple home tool: a printed square grid with a central dot. Cover one eye, look at the dot from reading distance — do the straight lines bend, blur or disappear? Repeat with the other eye, daily or weekly. New distortion = possible dry-to-wet conversion = same-week OCT. It costs nothing, takes ten seconds, and has saved countless maculas — every AMD patient of ours gets one.

Every guide below is written by the same surgeon who would operate on you:

From drjigneshgalaeye.com

From crystalcleareye.in

Your retina deserves a specialist. Today, not someday.

AMD is a marathon, not a sprint — and 2026’s prices and drugs finally make the marathon winnable.

📍 Andheri West: Laram Centre CHS, A1-202, S.V. Road, above Sunil Jewellers, near NADCO Shopping Centre, Mumbai 400058
📍 Vile Parle East: Topax Eye Hospital • Open daily, closes 9 pm

📞 Call 077188 85245 💬 WhatsApp Us

Dr. Jignesh Gala, FRCS (Glasgow) — Vitreoretinal & Cataract Surgeon • drjigneshgalaeye.com • crystalcleareye.in

Medical disclaimer: This page is educational and does not replace a personal consultation. Prices are indicative, verified on 24 July 2026, and may change. Every eye is different — decisions are made only after examination by Dr. Jignesh Gala.

Research & Evidence Library — 109 Verified References

Every link verified live in July 2026 (official NCBI E-utilities). This is the research Dr. Gala reads — click any title to verify the science yourself.

IVT: Faricimab (Vabysmo) Trials

  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. — Lancet (London, England), 2022
  2. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. — Ophthalmology, 2024
  3. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. — Lancet (London, England), 2022
  4. Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial. — Ophthalmology, 2026
  5. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. — Ophthalmology, 2019
  6. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. — Ophthalmology, 2024
  7. Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration. — Ophthalmology, 2025
  8. Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials. — Ophthalmology. Retina, 2025
  9. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. — Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024

IVT: Aflibercept 8 Mg (Photon / Pulsar)

  1. Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials. — Ophthalmology and therapy, 2025
  2. A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. — Ophthalmic research, 2026
  3. Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US. — Ophthalmology and therapy, 2025
  4. Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON. — Ophthalmology and therapy, 2026
  5. A Response to: Letter to the Editor Regarding “Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials”. — Ophthalmology and therapy, 2026
  6. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. — JAMA ophthalmology, 2023
  7. High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? — Life (Basel, Switzerland), 2025
  8. Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series. — BMC ophthalmology, 2024
  9. Clinical Outcomes of High-Dose Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis. — Cureus, 2026
  10. Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular Degeneration. — Ophthalmology. Retina, 2025

IVT: Brolucizumab

  1. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. — Ophthalmology, 2021
  2. Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam’s Razor? — Ocular immunology and inflammation, 2022
  3. [Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies]. — Vestnik oftalmologii, 2024
  4. RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence. — Retina (Philadelphia, Pa.), 2023
  5. EXUDATIVE RETINAL DETACHMENT AFTER INTRAVITREAL BROLUCIZUMAB INJECTION. — Retinal cases & brief reports, 2023
  6. Retinal vasculitis after intravitreal injection of brolucizumab. — Canadian journal of ophthalmology. Journal canadien d’ophtalmologie, 2022
  7. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. — Ophthalmology, 2020
  8. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. — Journal of vitreoretinal diseases, 2021
  9. Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. — Journal of vitreoretinal diseases, 2020
  10. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. — American journal of ophthalmology, 2022

IVT: Anti-Vegf For Neovascular Amd

  1. VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration. — International journal of molecular sciences, 2025
  2. Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era. — Eye (London, England), 2024
  3. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. — Science translational medicine, 2022
  4. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. — Progress in retinal and eye research, 2021
  5. [Anti-VEGF therapy resistance in neovascular age-related macular degeneration]. — Vestnik oftalmologii, 2017
  6. Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues. — Eye (London, England), 2025
  7. Anti-angiogenic biomolecules in neovascular age-related macular degeneration; therapeutics and drug delivery systems. — International journal of pharmaceutics, 2024
  8. Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization. — Biomolecules, 2024
  9. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). — The British journal of ophthalmology, 2014
  10. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. — Drug design, development and therapy, 2016

EYLEA: View 1 & View 2 — Wet Amd Pivotal Trials

  1. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. — Ophthalmology, 2012
  2. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. — Ophthalmology, 2014
  3. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials. — American journal of ophthalmology, 2019
  4. Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: VIEW 1 Extension Study. — Ophthalmology. Retina, 2017
  5. 2-Year Real-World Outcomes with Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: Literature Review and Meta-analysis of Patient-Relevant Outcomes. — Ophthalmology and therapy, 2021

EYLEA: Aflibercept Biosimilars (Sb15, Myl-1701P, Sdz-Afl, Abp 938, Ql1207)

  1. Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. — JAMA ophthalmology, 2023
  2. Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial. — BMJ open ophthalmology, 2023
  3. Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial. — JAMA ophthalmology, 2024
  4. EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study. — Retina (Philadelphia, Pa.), 2024
  5. Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration. — Ophthalmology. Retina, 2026

EYLEA: Treat-And-Extend & Real World

  1. Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. — Ophthalmology and therapy, 2024
  2. Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration. — Canadian journal of ophthalmology, 2025
  3. Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom. — Life (Basel, Switzerland), 2025
  4. Early Outcome of Aflibercept 8 mg for Neovascular AMD in the Real-world Setting. — Klinische Monatsblatter fur Augenheilkunde, 2025

EYLEA: Safety

  1. Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials. — Ophthalmology, 2016
  2. Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS). — Frontiers in pharmacology, 2022
  3. Noninfectious Intraocular Inflammation After Intravitreal Aflibercept. — JAMA ophthalmology, 2025
  4. Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study. — Canadian journal of ophthalmology, 2026

OCT: Age-Related Macular Degeneration Biomarkers

  1. OCT Prognostic Biomarkers for Progression to Late Age-related Macular Degeneration: A Systematic Review and Meta-analysis — Ophthalmology. Retina, 2024
  2. Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration: A Meta-Analysis — Ophthalmology, 2025
  3. Choroidal biomarkers in age-related macular degeneration — Survey of ophthalmology, 2025
  4. Practical guidance for imaging biomarkers in exudative age-related macular degeneration — Survey of ophthalmology, 2023
  5. Predicting Progression of Age-Related Macular Degeneration Using OCT and Fundus Photography — Ophthalmology. Retina, 2021

COST: Anti-Vegf Cost-Effectiveness (Amd)

  1. Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective. — Arquivos brasileiros de oftalmologia, 2020
  2. Cost effectiveness of treatments for wet age-related macular degeneration. — PharmacoEconomics, 2011
  3. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. — PloS one, 2018

COST: Bevacizumab Vs Ranibizumab Cost-Effectiveness

  1. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. — The British journal of ophthalmology, 2007
  2. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. — Ophthalmology, 2014
  3. Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review. — Ophthalmology, 2016
  4. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. — BMJ open, 2014

COST: Aflibercept Cost-Effectiveness

  1. Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. — JAMA ophthalmology, 2023
  2. Cost-effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China. — Journal of comparative effectiveness research, 2020
  3. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data. — Journal of medical economics, 2020
  4. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy. — BMC health services research, 2022

COST: Faricimab (Vabysmo) Cost-Effectiveness

  1. Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan. — Journal of medical economics, 2025
  2. Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis. — PharmacoEconomics – open, 2024
  3. Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China. — Journal of comparative effectiveness research, 2026
  4. Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia. — Journal of health economics and outcomes research, 2025

COST: Biosimilars & Cost Savings

  1. Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan. — Ophthalmology and therapy, 2023
  2. Budget impact analysis of the introduction of ranibizumab’s biosimilar to the Jordanian joint procurement system. — Frontiers in public health, 2026
  3. Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period. — Health affairs (Project Hope), 2014
  4. Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. — Indian journal of ophthalmology, 2026

COST: Anti-Vegf Cost In India (Dme)

  1. Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population. — Clinical ophthalmology (Auckland, N.Z.), 2021
  2. Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in näive patients with diabetic macular edema. — Indian journal of pharmacology, 2024
  3. Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact. — Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2017

COST: Treat-And-Extend Cost-Minimisation

  1. Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration. — Graefe’s archive for clinical and experimental ophthalmology, 2022
  2. Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland. — Journal of medical economics, 2025
  3. A cost-minimization analysis of anti-VEGFs for the treatment of neovascular age-related macular degeneration in the Netherlands. — Graefe’s archive for clinical and experimental ophthalmology, 2025

COST: Dexamethasone Implant Cost-Effectiveness

  1. Cost-Effectiveness of Dexamethasone Intravitreal Implant in Naïve and Previously Treated Patients with Diabetic Macular Edema. — International journal of environmental research and public health, 2023
  2. Dexamethasone implant for non-infectious uveitis: is it cost-effective? — The British journal of ophthalmology, 2019
  3. Cost-effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: A Markov-model. — Acta ophthalmologica, 2021
  4. Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema. — Cost effectiveness and resource allocation : C/E, 2022

COST: Treatment Burden & Indirect Costs

  1. Treatment burden on patients receiving intravitreal anti-VEGF for wet age-related macular degeneration. — Acta ophthalmologica, 2024
  2. Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia. — Diabetes, metabolic syndrome and obesity : targets and therapy, 2019
  3. Optimizing the invisible costs of anti-VEGF: The road to regularity. — Indian journal of ophthalmology, 2026

IVT: Myopic Choroidal Neovascularization

  1. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. — Expert opinion on drug safety, 2022
  2. IMI Pathologic Myopia. — Investigative ophthalmology & visual science, 2021
  3. Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy. — Drugs, 2016
  4. The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook. — Expert opinion on biological therapy, 2016
  5. Ranibizumab for myopic choroidal neovascularization. — Expert opinion on biological therapy, 2020
  6. Anti-VEGF Therapy in Myopic CNV. — Current drug targets, 2021
  7. Pharmacotherapy of Myopic Choroidal Neovascularization. — Current pharmaceutical design, 2018
  8. Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment. — PloS one, 2022
  9. Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application. — Drug design, development and therapy, 2015
  10. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. — Ophthalmology, 2017

EYLEA: Myrror — Myopic Cnv

  1. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. — Ophthalmology, 2015
  2. Influence of myopic macular degeneration severity on treatment outcomes with intravitreal aflibercept in the MYRROR study. — Acta ophthalmologica, 2019

IVT: Retinal Vein Occlusion Anti-Vegf

  1. Integrated Assessment of OCT, Multimodal Imaging, and Cytokine Markers for Predicting Treatment Responses in Retinal Vein Occlusion Associated Macular Edema: A Comparative Review of Anti-VEGF and Steroid Therapies. — Diagnostics (Basel, Switzerland), 2024
  2. [Retinal vein occlusion: anti-VEGF treatments]. — Journal francais d’ophtalmologie, 2009
  3. Retinal Vein Occlusion. — Developments in ophthalmology, 2016